Evaluation of topotecan in resistant and relapsing multiple myeloma: A southwest oncology group study

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 589-592

  Kraut, Eric H ^a   Crowley, John J ^a   Wade, James L ^a   Laufman, Leslie R ^a   Alsina, Melissa ^a   Taylor, Sarah A ^a   Salmon, Sydney E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; GRANULOCYTOPENIA; HUMAN; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031942348     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.589     Document Type: Article

References (21)

1. Kyle RA: Diagnosis and management of multiple myeloma and related disorders. Prog Hematol 14:257-282, 1996
2. Buzaid AC, Durie BG: Management of refractory myeloma - A review. J Clin Oncol 6:889-905, 1988
3. Attal M, Harousseau J, Stoppa A, et al: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
4. Blade J, San Miguel J, Fontanillas M, et al: Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/auto transplantation and who were conventionally treated. J Clin Oncol 14:2167-2173, 1996
5. Slichenmeyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as anti tumor agents. J Natl Cancer Inst 85:271-289, 1993
6. D'arpa P, Liu LF: Topoisomerase targeting anti tumor drugs. Biochem Biophys Acta 989:163-177, 1989
7. Tanizawa A, Fujimiori A, Pommier Y: Comparison of topoisomerase I inhibitors, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Institute 86:836-842, 1994
8. Hsiang YH, Liu LF, Wall M, et al: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4835-4839, 1989
9. Johnson RK, McCabe FL, Faucette LF, et al: SCF 104684 a water soluble analog of camptothecan with broad spectrum activity in preclinical models. Proc Am Assoc Cancer Res 30:623, 1989 (abstr)
10. Burns HA, Fields SM: Topoisomerase I inhibitors. Hematol Oncol Clin North Am 8:333-355, 1994
11. Rowinsky EK, Gochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan. A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
12. Kantarjian H, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993
13. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11. A new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
14. Green S, Weiss G: Southwest Oncology Group, standard response criteria, end point definitions and toxicity criteria. Invest New Drugs 10:239-253 1992
15. Durie BG, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842-854, 1975
16. Alexanian R, Burlogle B, Dixon D: High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105:8-11, 1986
17. Durie BG, Salmon SE: The current status and future prospects of treatment for multiple myeloma in "myeloma and related disorders". Clin Hematol 1:181-210, 1982
18. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984
19. Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK+F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992
20. Sonneveld P, Durie BG, Lokhorst HM, et al: Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 340:255-259, 1992
21. Salmon SE, Dalton WS, Grogan TM, et al: Multidrug resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50, 1991